Sorafenib
anti-angiogenic multi-kinase inhibitor used in the therapy of refractory metastatic colorectal cancer, hepatocellular carcinoma and gastrointestinal stromal tumor. close to Regorafenib. Inhibitor of sEH
General
Type : Urea derivative, Not AlphaBeta Hydrolase target, Trifluoro, Carboxamide, multi-kinase inhibitor
Chemical_Nomenclature : 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
Canonical SMILES : CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F
InChI : InChI=1S\/C21H16ClF3N4O3\/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25\/h2-11H,1H3,(H,26,30)(H2,28,29,31)
InChIKey : MLDQJTXFUGDVEO-UHFFFAOYSA-N
Other name(s) : Nexavar || BAY 43-9006 || CHEMBL1336 || CHEBI:50924
MW : 464.82
Formula : C21H16ClF3N4O3
CAS_number : 284461-73-0
PubChem : 216239
UniChem : MLDQJTXFUGDVEO-UHFFFAOYSA-N
Target
Families : Sorafenib ligand of proteins in family
Epoxide_hydrolase
Protein :
human-EPHX2
mouse-hyes
References (9)
| Title : Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors - Hwang_2013_Bioorg.Med.Chem.Lett_23_3732 |
| Author(s) : Hwang SH , Wecksler AT , Zhang G , Morisseau C , Nguyen LV , Fu SH , Hammock BD |
| Ref : Bioorganic & Medicinal Chemistry Lett , 23 :3732 , 2013 |
| Abstract : |
| PubMedSearch : Hwang_2013_Bioorg.Med.Chem.Lett_23_3732 |
| PubMedID: 23726028 |
| Title : Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors - Hwang_2013_Bioorg.Med.Chem.Lett_23_3732 |
| Author(s) : Hwang SH , Wecksler AT , Zhang G , Morisseau C , Nguyen LV , Fu SH , Hammock BD |
| Ref : Bioorganic & Medicinal Chemistry Lett , 23 :3732 , 2013 |
| Abstract : |
| PubMedSearch : Hwang_2013_Bioorg.Med.Chem.Lett_23_3732 |
| PubMedID: 23726028 |
| Title : Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors - Hwang_2013_Bioorg.Med.Chem.Lett_23_3732 |
| Author(s) : Hwang SH , Wecksler AT , Zhang G , Morisseau C , Nguyen LV , Fu SH , Hammock BD |
| Ref : Bioorganic & Medicinal Chemistry Lett , 23 :3732 , 2013 |
| Abstract : |
| PubMedSearch : Hwang_2013_Bioorg.Med.Chem.Lett_23_3732 |
| PubMedID: 23726028 |
| Title : Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy - Inoue_2011_Cancer.Biol.Ther_12_827 |
| Author(s) : Inoue H , Hwang SH , Wecksler AT , Hammock BD , Weiss RH |
| Ref : Cancer Biol Ther , 12 :827 , 2011 |
| Abstract : |
| PubMedSearch : Inoue_2011_Cancer.Biol.Ther_12_827 |
| PubMedID: 21878748 |
| Title : Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy - Inoue_2011_Cancer.Biol.Ther_12_827 |
| Author(s) : Inoue H , Hwang SH , Wecksler AT , Hammock BD , Weiss RH |
| Ref : Cancer Biol Ther , 12 :827 , 2011 |
| Abstract : |
| PubMedSearch : Inoue_2011_Cancer.Biol.Ther_12_827 |
| PubMedID: 21878748 |
| Title : Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy - Inoue_2011_Cancer.Biol.Ther_12_827 |
| Author(s) : Inoue H , Hwang SH , Wecksler AT , Hammock BD , Weiss RH |
| Ref : Cancer Biol Ther , 12 :827 , 2011 |
| Abstract : |
| PubMedSearch : Inoue_2011_Cancer.Biol.Ther_12_827 |
| PubMedID: 21878748 |
| Title : Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo - Liu_2009_Mol.Cancer.Ther_8_2193 |
| Author(s) : Liu JY , Park SH , Morisseau C , Hwang SH , Hammock BD , Weiss RH |
| Ref : Mol Cancer Ther , 8 :2193 , 2009 |
| Abstract : |
| PubMedSearch : Liu_2009_Mol.Cancer.Ther_8_2193 |
| PubMedID: 19671760 |
| Title : Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo - Liu_2009_Mol.Cancer.Ther_8_2193 |
| Author(s) : Liu JY , Park SH , Morisseau C , Hwang SH , Hammock BD , Weiss RH |
| Ref : Mol Cancer Ther , 8 :2193 , 2009 |
| Abstract : |
| PubMedSearch : Liu_2009_Mol.Cancer.Ther_8_2193 |
| PubMedID: 19671760 |
| Title : Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo - Liu_2009_Mol.Cancer.Ther_8_2193 |
| Author(s) : Liu JY , Park SH , Morisseau C , Hwang SH , Hammock BD , Weiss RH |
| Ref : Mol Cancer Ther , 8 :2193 , 2009 |
| Abstract : |
| PubMedSearch : Liu_2009_Mol.Cancer.Ther_8_2193 |
| PubMedID: 19671760 |